Clinical Need
Failure of saphenous vein grafts in CABG is a highly significant problem. read more
Our Solution
Angioshield™ promises to improve vein performance and longevity in coronary artery bypass grafts. read more

Introducing Angioshield™


Over 13 million patients currently suffer from coronary heart disease, the leading cause of morbidity worldwide. Coronary artery bypass graft (CABG) remains the gold standard with nearly 300,000 surgeries performed annually in the U.S. alone.

… Angioshield™ is a new paradigm for treatment of coronary artery disease and promises to improve vein performance and longevity in coronary artery bypass grafts.

Failure of saphenous vein grafts in CABG is a highly significant problem. As many as 30% of these grafts become occluded in the first year and the failure rate is as great at 50% at five years. Failed grafts cause significant morbidity, vastly impaired quality of life, and frequently require reintervention.

NeoGraft Technologies is developing Angioshield™, an intraperative system that creates a micro-fibrous, polymer sleeve intimately surrounding the outside surface of a harvested vein to mechanically reinforce and protect it from overdilation.